207 related articles for article (PubMed ID: 28050766)
1. Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis.
Denbo JW; Slack RS; Bruno M; Cloyd JM; Prakash L; Fleming JB; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MH
J Gastrointest Surg; 2017 Apr; 21(4):636-646. PubMed ID: 28050766
[TBL] [Abstract][Full Text] [Related]
2. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.
Ma LW; Dominguez-Rosado I; Gennarelli RL; Bach PB; Gonen M; D'Angelica MI; DeMatteo RP; Kingham TP; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2017 Jan; 265(1):11-16. PubMed ID: 27429029
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery.
Welsch T; Müssle B; Distler M; Knoth H; Weitz J; Häckl D
Langenbecks Arch Surg; 2016 Nov; 401(7):1027-1035. PubMed ID: 27233242
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis.
Goyert N; Eeson G; Kagedan DJ; Behman R; Lemke M; Hallet J; Mittmann N; Law C; Karanicolas PJ; Coburn NG
Ann Surg; 2017 Jan; 265(1):2-10. PubMed ID: 27537539
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide administration after pancreaticoduodenectomy may decrease clinically relevant postoperative pancreatic fistula in high-risk patients with small pancreatic ducts, soft pancreatic parenchyma and cystic or neuroendocrine neoplasia.
Vuorela T; Mustonen H; Kokkola A; Haglund C; Seppänen H
Pancreatology; 2020 Jun; 20(4):757-761. PubMed ID: 32307251
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide is not effective in reducing the development of postoperative pancreatic fistula.
Young S; Sung ML; Lee JA; DiFronzo LA; O'Connor VV
HPB (Oxford); 2018 Sep; 20(9):834-840. PubMed ID: 30060910
[TBL] [Abstract][Full Text] [Related]
7. Risk-stratified analysis of pasireotide for patients undergoing pancreatectomy.
Peng JS; Joyce D; Brady M; Groman A; Attwood K; Kuvshinoff B; Hochwald SN; Kukar M
J Surg Oncol; 2020 Aug; 122(2):195-203. PubMed ID: 32474957
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.
Abbott DE; Sutton JM; Jernigan PL; Chang A; Frye P; Shah SA; Schauer DP; Eckman MH; Ahmad SA; Sussman JJ
J Surg Oncol; 2016 Jun; 113(7):784-8. PubMed ID: 27041733
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GJ
Am Surg; 2020 Dec; 86(12):1728-1735. PubMed ID: 32870029
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after Pancreatectomy with Routine Pasireotide Use.
Kunstman JW; Goldman DA; Gönen M; Balachandran VP; D'Angelica MI; Kingham TP; Jarnagin WR; Allen PJ
J Am Coll Surg; 2019 Feb; 228(2):161-170.e2. PubMed ID: 30414453
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Dalton EC; Johns MS; Rhodes L; Merritt WT; Petrelli NJ; Tiesi GG
Am Surg; 2020 May; 86(5):429-436. PubMed ID: 32684027
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for postoperative pancreatic fistula in the Era of pasireotide.
Potter KC; Sutton TL; O'Grady J; Gilbert EW; Pommier R; Mayo SC; Sheppard BC
Am J Surg; 2022 Aug; 224(2):733-736. PubMed ID: 35221100
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide for postoperative pancreatic fistula.
Allen PJ; Gönen M; Brennan MF; Bucknor AA; Robinson LM; Pappas MM; Carlucci KE; D'Angelica MI; DeMatteo RP; Kingham TP; Fong Y; Jarnagin WR
N Engl J Med; 2014 May; 370(21):2014-22. PubMed ID: 24849084
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pasireotide for Prevention of Postoperative Pancreatic Fistula in Pancreatic Surgery: a Systematic Review and Meta-analysis.
Liu X; Pausch T; Probst P; Cui J; Wei J; Hackert T; Miao Y
J Gastrointest Surg; 2020 Jun; 24(6):1421-1429. PubMed ID: 32207077
[TBL] [Abstract][Full Text] [Related]
15. Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula: A Randomized Clinical Trial.
Tarvainen T; Sirén J; Kokkola A; Sallinen V
JAMA Surg; 2020 Apr; 155(4):291-298. PubMed ID: 32022887
[TBL] [Abstract][Full Text] [Related]
16. Predicting pancreatic fistula after central pancreatectomy using current fistula risk scores for pancreaticoduodenectomy and distal pancreatectomy.
Yang F; Xu Y; Jin C; Windsor JA; Fu D
Pancreatology; 2023 Nov; 23(7):843-851. PubMed ID: 37739874
[TBL] [Abstract][Full Text] [Related]
17. Perioperative hydrocortisone treatment reduces postoperative pancreatic fistula rate after open distal pancreatectomy. A randomized placebo-controlled trial.
Antila A; Siiki A; Sand J; Laukkarinen J
Pancreatology; 2019 Jul; 19(5):786-792. PubMed ID: 31153781
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of risk factors for pancreatic fistula after pancreatoduodenectomy or distal pancreatectomy.
Halle-Smith JM; Vinuela E; Brown RM; Hodson J; Zia Z; Bramhall SR; Marudanayagam R; Sutcliffe RP; Mirza DF; Muiesan P; Isaac J; Roberts KJ
HPB (Oxford); 2017 Aug; 19(8):727-734. PubMed ID: 28522378
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide does not prevent postoperative pancreatic fistula: a prospective study.
Elliott IA; Dann AM; Ghukasyan R; Damato L; Girgis MD; King JC; Hines OJ; Reber HA; Donahue TR
HPB (Oxford); 2018 May; 20(5):418-422. PubMed ID: 29398424
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for postoperative pancreatic fistula following non-traumatic, pancreatic surgery. Retrospective observational study.
Mostafa A; Habeeb TA; Neri V; Elshahidy TM; A Fiad A
Ann Ital Chir; 2023; 94():435-442. PubMed ID: 38051507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
